Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial
Authors:
Open Access
Abstract
Background: Helicobacter pylori gastritis may progress to glandular atrophy and intestinal metaplasia, conditions that predispose to gastric cancer. Profound suppression of gastric acid is associated with increased severity of H pylori gastritis. This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD). Methods: A total of 231 H pylori positive GORD patients who had been treated for ⩾12 months with omeprazole maintenance therapy (OM) were randomised to either continuation of OM (OM only; n = 120) or OM plus a one week course of omeprazole, amoxycillin, and clarithromycin (OM triple; n = 111). Endoscopy with standardised biopsy sampling as well as symptom evaluation were performed at baseline and after one and two years. Gastritis was assessed according to the Sydney classification system for activity, inflammation, atrophy, intestinal metaplasia, and H pylori density. Results: Corpus gastritis activity at entry was moderate or severe in 50% and 55% of the OM only and OM triple groups, respectively. In the OM triple group, H pylori was eradicated in 90 (88%) patients, and activity and inflammation decreased substantially in both the antrum and corpus (pv two years). Atrophic gastritis also improved in the corpus (pH pylori eradication did not alter the dose of omeprazole required, or reflux symptoms. Conclusions: Most H pylori positive GORD patients have a corpus predominant pangastritis during omeprazole maintenance therapy. Eradication of H pylori eliminates gastric mucosal inflammation and induces regression of corpus glandular atrophy. H pylori eradication did not worsen reflux disease or lead to a need for increased omeprazole maintenance dose. We therefore recommend eradication of H pylori in GORD patients receiving long term acid suppression.Keywords
This publication has 53 references indexed in Scilit:
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2001
- Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasiaGut, 2001
- Changing Patterns of Helicobacter pylori Gastritis in Long‐Standing Acid SuppressionHelicobacter, 2000
- Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL‐cell hyperplasiaAlimentary Pharmacology & Therapeutics, 2000
- Atrophic gastritis during long‐term omeprazole therapy affects serum vitamin B12 levelsAlimentary Pharmacology & Therapeutics, 1999
- Lack of effect of acid suppression therapy on gastric atrophyGastroenterology, 1999
- The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapyAlimentary Pharmacology & Therapeutics, 1999
- Hypergastrinaemia during long‐term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1998
- Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.Gut, 1995
- Prevalence of Helicobacter pylori Infection and Histologic Gastritis in Asymptomatic PersonsNew England Journal of Medicine, 1989